Paul Melmeyer on How Therapies for Rare Diseases Present Challenges to Value Assessment

Video

Therapies for rare diseases, such as gene therapy, pose very unique challenges to value assessments in a variety of different ways, explained Paul Melmeyer, director of Federal Policy, National Organization for Rare Disorders.

Therapies for rare diseases, such as gene therapy, pose very unique challenges to value assessments in a variety of different ways, explained Paul Melmeyer, director of Federal Policy, National Organization for Rare Disorders.

Transcript

How do therapies for rare conditions, such as gene therapy, present unique challenges to value assessment?

Therapies for rare diseases, and especially gene therapies for rare diseases, pose very unique challenges to value assessments in a variety of different ways. For one, the values that therapies for rare diseases, again in particular gene therapies, actually bring to rare disease patients are very unique, and that can be challenging for health technology bodies to actually incorporate these values into their assessments because they can be very unique, they can be very hard to quantify, they can be hard to reach because rare disease patients are scattered, they’re difficult to often times to bring in to a conclusive and a methodologically robust way, in a sense, within a value technology assessment.

So, because of this, it can be very challenging for HTA [health technology assessment] bodies to actually incorporate patient viewpoints within rare disease and gene therapy evaluations, and that’s just on the patient viewpoint side of things. Of course, it can be very challenging on the actual methodological side of things when it comes to rare diseases because of, again, the small patient sizes. So, it’s more difficult to conduct an empirical study, as well as some other methodological challenges that come along with the small sample sizes that rare diseases bring. So, a variety of different challenges in assessing rare disease therapies, specifically gene therapies.

Recent Videos
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Sarah Hein, PhD, the chief executive officer and cofounder of March Biosciences
Brian Kim, MBA, the chief executive officer of Mission Bio
Related Content
© 2025 MJH Life Sciences

All rights reserved.